Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials-Reference-Cited by-同舟云学术

Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials

Published:2018-07-10 Issue:13 Volume:2 Page:1633-1644
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:Blood Adv

Author:

Chari Ajai,Stewart A. Keith,Russell Stuart D.,Moreau Philippe,Herrmann Joerg,Banchs Jose,Hajek Roman,Groarke John,Lyon Alexander R.,Batty George N.,Ro Sunhee,Huang Mei,Iskander Karim S.,Lenihan Daniel

Publisher

American Society of Hematology

Subject

Hematology

Reference49 articles.

1. The Progression From Hypertension to Congestive Heart Failure

2. The Role of Hypertension in the Pathogenesis of Heart Failure

3. Pathogenesis and treatment of renal failure in multiple myeloma

4. Kidney Disease and Multiple Myeloma

5. Current approach to diagnosis and management of acute renal failure in myeloma patients;Leung;Adv Chronic Kidney Dis,2012

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-19

2. Differential Expression of Circulating miRNAs and Carfilzomib-Related Cardiovascular Adverse Events in Patients with Multiple Myeloma;International Journal of Molecular Sciences;2024-07-16

3. Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging;Journal of Clinical Medicine;2024-06-26

4. Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA;American Journal of Hematology;2024-01-31

5. Successful management of camrelizumab-induced immune-checkpoint-inhibitors-related myocarditis;Journal of Oncology Pharmacy Practice;2023-12-03